Please enable Javascript to use all features and improve your user experience.
EHC 2023
Programme
People
Search
DE
All people
Uwe Reuter
Sort by Type
Date
Chair
06/12/2023
14:40
–
15:55
Plenary session
PS 3 & Opening | Role of the calvarium, brain immune barriers and fluid transport
Plenary hall
07/12/2023
09:45
–
11:15
Scientific session
ScS 4 | Biomarkers and pathophysiology in migraine
Breakout room 1
07/12/2023
14:00
–
15:15
Debate session
DS 1 | The EHF debate on acute migraine medication
Plenary hall
Invited speaker
Other
Welcome by the congress chairs
Speaker
ePoster
P019
Benefit-Risk assessment of atogepant vs. placebo in participants with episodic migraine who had prior inadequate response to 2–4 classes of oral preventive treatment: a post-hoc analysis of the ELEVATE trial
Further involvements
ePoster
P019
Benefit-Risk assessment of atogepant vs. placebo in participants with episodic migraine who had prior inadequate response to 2–4 classes of oral preventive treatment: a post-hoc analysis of the ELEVATE trial
ePoster
P022
Atogepant demonstrates early functional and quality of life improvements for the preventive treatment of episodic migraine after prior inadequate response to treatment: results from the ELEVATE trial
ePoster
P179
Visual snow syndrome in patients with migraine from a tertiary headache center: prevalence, phenomenology and impact on quality of life
ePoster
P180
Alice in Wonderland Syndrome (AIWS) and migraine: prevalence and characteristics of AIWS in adults with migraine
ePoster
P096
Atogepant provides early improvements in daily functioning and quality of life: results from the PROGRESS chronic migraine trial
ePoster
LP051
Reimbursement rules for CGRP mAbs throughout europe: an overview of the various constraints used
ePoster
P260
Predictors of response to anti-CGRP monoclonal antibodies: a scoping review and meta-analysis of real-world experience
© Conventus Congressmanagement & Marketing GmbH
Imprint
Privacy